Functional assays revealed that genetic and pharmacological suppression of HAX-1 restored autophagic flux, reduced SQSTM1 accumulation, and sensitised NPC cells to cisplatin in vitro and in xenograft models [52]. Here, HAX1 is linked to nasopharyngeal carcinoma.